IMPAX to Present at Merrill Lynch's Global Pharmaceutical, Biotechnology and Medical Device Conference

February 01, 2008

HAYWARD, Calif.--(BUSINESS WIRE)--Feb. 1, 2008--IMPAX Laboratories, Inc. (OTC: IPXL) today announced that Arthur A. Koch, Jr., its senior vice president and chief financial officer, will present at Merrill Lynch's Global Pharmaceutical, Biotechnology and Medical Device Conference on Thursday, February 7th, at 2:20 p.m. Eastern Time. The conference will be held at the Grand Hyatt New York from February 5 to 7, 2008.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at To listen to the live presentation, please go to the web site 15 minutes prior to its start to register, download, and install the necessary audio software. This presentation will be archived on the Company's web site for 90 days.

About IMPAX Laboratories, Inc.

IMPAX Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. IMPAX markets its generic products through its Global Pharmaceuticals division and markets its branded products through the IMPAX Pharmaceuticals division. Additionally, where strategically appropriate, IMPAX has developed marketing partnerships to fully leverage its technology platform. IMPAX Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more information, please visit the Company's Web site at:

CONTACT: IMPAX Laboratories, Inc.
Larry Hsu, Ph.D., President & CEO
510-476-2000, Ext. 1111
Arthur A. Koch, Jr., Sr. VP & CFO
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212-838-3777
Bruce Voss, 310-691-7100

SOURCE: IMPAX Laboratories, Inc.